1. Is it time for biosimilars in autoimmune diseases?;Cuadrado;Autoimmun Rev,2013
2. EMA. EMEA/CHMP/BMWP/42832/2005 Rev1: Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues; 18 December 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf. Accessed May 15, 2016.
3. Putting the value into biosimilar decision making: the judgment value criteria;Mendes de Abreu;Autoimmun Rev,2014
4. Antibody engineering to develop new antirheumatic therapies;Isaacs;Arthritis Res Ther,2009
5. Phage display derived therapeutic antibodies;Thie;Curr Pharm Biotechnol,2008